13D Filing: Levin Capital Strategies and Fluidigm Corp (FLDM)

Fluidigm Corp (NASDAQ:FLDM): John A. Levin’s Levin Capital Strategies filed an amended 13D.

You can check out Levin Capital Strategies’ latest holdings and filings here.

Please follow Levin Capital Strategies (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Levin Capital Strategies or update its stock holdings.

Follow John A. Levin's Levin Capital Strategies

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Levin Capital Strategies 0 0 12,424,234 12,424,234 32.1%
Levin Capital Strategies GP 0 0 12,424,234 12,424,234 32.1%
Bi-Directional Disequilibrium Master Fund, Ltd. (f k a Levin Capital Trilogy Master Fund, Ltd.) 0 0 89,363 89,363 Less than 1%
LCS 0 0 89,363 89,363 Less than 1%
Levcap Alternative Fund 0 0 56,820 56,820 Less than 1%
LCS Event Partners 0 0 56,820 56,820 Less than 1%
Safinia Partners 0 0 19,818 19,818 Less than 1%
LCS L S 0 0 19,818 19,818 Less than 1%
John A. Levin 5,000 5,000 12,424,234 12,429,234 32.2%

Follow John A. Levin's Levin Capital Strategies

Page 1 of 18 – SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE
COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Rule 13d-101)

INFORMATION TO BE INCLUDED
IN STATEMENTS FILED PURSUANT

TO § 240.13d-1(a)
AND AMENDMENTS THERETO FILED PURSUANT TO

§ 240.13d-2(a)

(Amendment No. 3)1

Fluidigm Corporation

(Name
of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

34385P108

(CUSIP Number)

John A. Levin

Levin Capital Strategies, L.P.

595 Madison Avenue, 17th Floor

New York, NY 10022

(212) 259-0800

(Name, Address and Telephone Number of Person

Authorized to Receive Notices
and Communications)

March 2, 2018

(Date of Event Which Requires
Filing of This Statement)

If
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule
13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following
box
¨.

Note:  Schedules
filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See
§ 240.13d-7 for other parties to whom copies are to be sent.

1
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided
in a prior cover page.

The information required
on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).

Follow Standard Biotools Inc. (NASDAQ:LAB)

Page 2 of 18 – SEC Filing

1 NAME OF REPORTING PERSON
Levin Capital Strategies, L.P.
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
(b) ☐
3 SEC USE ONLY
4 SOURCE OF FUNDS
WC, AF
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY 0
OWNED BY 8 SHARED VOTING POWER
EACH
REPORTING 9,314,997
PERSON WITH 9 SOLE DISPOSITIVE POWER
0
10 SHARED DISPOSITIVE POWER
12,424,234
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
12,424,234
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
32.1%
14 TYPE OF REPORTING PERSON
IA
2

Follow Standard Biotools Inc. (NASDAQ:LAB)

Page 3 of 18 – SEC Filing

1 NAME OF REPORTING PERSON
Levin Capital Strategies GP, LLC
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
(b) ☐
3 SEC USE ONLY
4 SOURCE OF FUNDS
AF
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY 0
OWNED BY 8 SHARED VOTING POWER
EACH
REPORTING 9,314,997
PERSON WITH 9 SOLE DISPOSITIVE POWER
0
10 SHARED DISPOSITIVE POWER
12,424,234
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
12,424,234
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
32.1%
14 TYPE OF REPORTING PERSON
OO
3

Follow Standard Biotools Inc. (NASDAQ:LAB)

Page 4 of 18 – SEC Filing

1 NAME OF REPORTING PERSON
Bi-Directional Disequilibrium Master Fund, Ltd. (f/k/a Levin Capital Trilogy Master Fund, Ltd.)
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
(b) ☐
3 SEC USE ONLY
4 SOURCE OF FUNDS
WC
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY 0
OWNED BY 8 SHARED VOTING POWER
EACH
REPORTING 89,363
PERSON WITH 9 SOLE DISPOSITIVE POWER
0
10 SHARED DISPOSITIVE POWER
89,363
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
89,363
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
Less than 1%
14 TYPE OF REPORTING PERSON
CO
4

Follow Standard Biotools Inc. (NASDAQ:LAB)

Page 5 of 18 – SEC Filing

1 NAME OF REPORTING PERSON
LCS, LLC
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
(b) ☐
3 SEC USE ONLY
4 SOURCE OF FUNDS
AF
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY 0
OWNED BY 8 SHARED VOTING POWER
EACH
REPORTING 89,363
PERSON WITH 9 SOLE DISPOSITIVE POWER
0
10 SHARED DISPOSITIVE POWER
89,363
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
89,363
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
Less than 1%
14 TYPE OF REPORTING PERSON
OO
5

Follow Standard Biotools Inc. (NASDAQ:LAB)

Page 6 of 18 – SEC Filing

1 NAME OF REPORTING PERSON
Levcap Alternative Fund, L.P.
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
(b) ☐
3 SEC USE ONLY
4 SOURCE OF FUNDS
WC
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY 0
OWNED BY 8 SHARED VOTING POWER
EACH
REPORTING 56,820
PERSON WITH 9 SOLE DISPOSITIVE POWER
0
10 SHARED DISPOSITIVE POWER
56,820
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
56,820
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
Less than 1%
14 TYPE OF REPORTING PERSON
PN
6

Follow Standard Biotools Inc. (NASDAQ:LAB)

Page 7 of 18 – SEC Filing

1 NAME OF REPORTING PERSON
LCS Event Partners, LLC
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
(b) ☐
3 SEC USE ONLY
4 SOURCE OF FUNDS
AF
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY 0
OWNED BY 8 SHARED VOTING POWER
EACH
REPORTING 56,820
PERSON WITH 9 SOLE DISPOSITIVE POWER
0
10 SHARED DISPOSITIVE POWER
56,820
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
56,820
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
Less than 1%
14 TYPE OF REPORTING PERSON
OO
7

Follow Standard Biotools Inc. (NASDAQ:LAB)

Page 8 of 18 – SEC Filing

1 NAME OF REPORTING PERSON
Safinia Partners, L.P.
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
(b) ☐
3 SEC USE ONLY
4 SOURCE OF FUNDS
WC
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY 0
OWNED BY 8 SHARED VOTING POWER
EACH
REPORTING 19,818
PERSON WITH 9 SOLE DISPOSITIVE POWER
0
10 SHARED DISPOSITIVE POWER
19,818
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
19,818
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
Less than 1%
14 TYPE OF REPORTING PERSON
PN
8

Follow Standard Biotools Inc. (NASDAQ:LAB)

Page 9 of 18 – SEC Filing

1 NAME OF REPORTING PERSON
LCS L/S, LLC
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
(b) ☐
3 SEC USE ONLY
4 SOURCE OF FUNDS
AF
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY 0
OWNED BY 8 SHARED VOTING POWER
EACH
REPORTING 19,818
PERSON WITH 9 SOLE DISPOSITIVE POWER
0
10 SHARED DISPOSITIVE POWER
19,818
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
19,818
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
Less than 1%
14 TYPE OF REPORTING PERSON
OO
9

Follow Standard Biotools Inc. (NASDAQ:LAB)

Page 10 of 18 – SEC Filing

1 NAME OF REPORTING PERSON
John A. Levin
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
(b) ☐
3 SEC USE ONLY
4 SOURCE OF FUNDS
AF
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States of America
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY 5,000
OWNED BY 8 SHARED VOTING POWER
EACH
REPORTING 9,314,997
PERSON WITH 9 SOLE DISPOSITIVE POWER
5,000
10 SHARED DISPOSITIVE POWER
12,424,234
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
12,429,234
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
32.2%
14 TYPE OF REPORTING PERSON
IN
10

Follow Standard Biotools Inc. (NASDAQ:LAB)

Page 11 of 18 – SEC Filing

The following constitutes
Amendment No. 3 to the Schedule 13D filed by the undersigned (the “Amendment No. 3”). This Amendment No. 3 amends the
Schedule 13D as specifically set forth herein.

ITEM 2. IDENTITY AND BACKGROUND

Item 2 is hereby
amended to add the following:

Effective February
28, 2018, Levin Capital Trilogy Master Fund, Ltd. changed its name to Bi-Directional Disequilibrium Master Fund, Ltd. (“Bi-Directional”).

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

Item 3 is hereby
amended and restated as follows:

The Shares
purchased by LCS on behalf of separately managed accounts, including Transamerica Large Cap Value Fund, a registered
investment company under the Investment Company Act of 1940, as amended (“Transamerica”), for which LCS acts as
sub-investment advisor, were purchased with general investment funds in open market purchases, except as otherwise noted. The
aggregate purchase price of the 12,258,233 Shares held in separately managed accounts that are beneficially owned directly by
LCS is approximately $60,347,703, including brokerage commissions.

The Shares purchased
by Bi-Directional were purchased with general investment funds in open market purchases, except as otherwise noted. The aggregate
purchase price of the 89,363 Shares owned directly by Bi-Directional is approximately $544,787,
i
ncluding brokerage commissions.

The Shares purchased
by Levcap were purchased with general investment funds in open market purchases, except as otherwise noted. The aggregate purchase
price of the 56,820 Shares owned directly by Levcap is approximately $280,825, including brokerage commissions.

The Shares purchased
by Safinia were purchased with general investment funds in open market purchases, except as otherwise noted. The aggregate purchase
price of the 19,818 Shares owned directly by Safinia is approximately $107,616, including brokerage commissions.

The Shares purchased
by John Levin’s wife were purchased with general investment funds in open market purchases, except as otherwise noted. The
aggregate purchase price of the 5,000 Shares owned directly by John Levin’s wife is approximately $39,359, including brokerage
commissions.

To the best of the
Reporting Persons’ knowledge, none of the persons listed on Appendix A beneficially owns any securities of the Issuer.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

Items 5(a)-(d) are
hereby amended and restated as follows:

The aggregate percentage
of Shares reported owned by each person named herein is based upon 38,647,687 Shares outstanding, which is the total number of
Shares outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission
on November 7, 2017.

11

Follow Standard Biotools Inc. (NASDAQ:LAB)

Page 12 of 18 – SEC Filing

A. LCS

(a)  As
of the close of business on March 5, 2018, LCS beneficially owned 12,424,234 Shares on behalf
of separately managed accounts, including 1,275,129 Shares held by the separately managed account Transamerica.

Percentage: Approximately 32.1%.

(b) 1. Sole power to vote
or direct vote: 0
2. Shared power to vote or direct vote: 9,314,997
3. Sole power to dispose or direct the disposition: 0
4. Shared power to dispose or direct the disposition: 12,424,234

(c)       The
transactions in the Shares by LCS on behalf of separately managed accounts, including Transamerica, since the filing of Amendment
No. 2 are set forth in Schedule A and are incorporated herein by reference.

B. LCS GP

(a)  As
the General Partner of LCS, LCS GP is deemed to beneficially own the 12,424,234 Shares beneficially owned by LCS.

Percentage: Approximately 32.1%.

(b) 1. Sole power to vote or direct vote: 0
2. Shared power to vote or direct vote: 9,314,997
3. Sole power to dispose or direct the disposition: 0
4. Shared power to dispose or direct the disposition: 12,424,234

(c)       LCS
GP has not undertaken any transactions in the Shares since the filing of Amendment No. 2.

C. Bi-Directional

(a)  As
of the close of business on March 5, 2018, Bi-Directional beneficially owned 89,363 Shares.

Percentage: Less than 1.0%.

(b) 1. Sole power to vote or direct vote: 0
2. Shared power to vote or direct vote: 89,363 *
3. Sole power to dispose or direct the disposition: 0
4. Shared power to dispose or direct the disposition: 89,363 *
12

Follow Standard Biotools Inc. (NASDAQ:LAB)

Page 13 of 18 – SEC Filing

*
As the general partner to Bi-Directional, LCSL has shared voting and dispositive power over these Shares. As the
investment
advisor to Bi-Directional, LCS has shared voting and dispositive power over these Shares.

(c)       The
transactions in the Shares by Bi-Directional since the filing of Amendment No. 2 are set forth in Schedule A and are incorporated
herein by reference.

D. LCSL

(a)  As
the General Partner of Bi-Directional, LCSL is deemed to beneficially own the 89,363 Shares beneficially owned by Bi-Directional.

Percentage: Less than 1.0%.

(b) 1. Sole power to vote or direct vote: 0
2. Shared power to vote or direct vote: 89,363 *
3. Sole power to dispose or direct the disposition: 0
4. Shared power to dispose or direct the disposition: 89,363 *

* As the general
partner to Bi-Directional, LCSL has shared voting and dispositive power over these Shares. As the investment advisor to Bi-Directional,
LCS has shared voting and dispositive power over these Shares.

(c)       LCSL
has not undertaken any transactions in the Shares since the filing of Amendment No. 2.

E. Levcap

(a)  As
of the close of business on March 5, 2018, Levcap beneficially owned 56,820 Shares.

Percentage: Less than 1.0%.

(b) 1. Sole power to vote or direct vote: 0
2. Shared power to vote or direct vote: 56,820 *
3. Sole power to dispose or direct the disposition: 0
4. Shared power to dispose or direct the disposition: 56,820*

* As the general
partner to Levcap, LCSEP has shared voting and dispositive power over these Shares. As the investment advisor to Levcap, LCS has
shared voting and dispositive power over these Shares.

(c)       Levcap
has not undertaken any transactions in the Shares since the filing of Amendment No. 2.

13

Follow Standard Biotools Inc. (NASDAQ:LAB)

Page 14 of 18 – SEC Filing

F. LCSEP

(a)  As
the General Partner of Levcap, LCSEP is deemed to beneficially own the 56,820 Shares beneficially
owned by Levcap.

Percentage: Less than 1.0%.

(b) 1. Sole power to vote or direct vote: 0
2. Shared power to vote or direct vote: 56,820 *
3. Sole power to dispose or direct the disposition: 0
4. Shared power to dispose or direct the disposition: 56,820*

* As the general partner to Levcap, LCSEP has
shared voting and dispositive power over these Shares. As the investment advisor to Levcap, LCS has shared voting and dispositive
power over these Shares.

(c)       LCSEP
has not undertaken any transactions in the Shares since the filing of Amendment No. 2.

G. Safinia

(a)  As
of the close of business on March 5, 2018, Safinia beneficially owned 19,818 Shares.

Percentage: Less than 1.0%.

(b) 1. Sole power to vote or direct vote: 0
2. Shared power to vote or direct vote: 19,818 *
3. Sole power to dispose or direct the disposition: 0
4. Shared power to dispose or direct the disposition:19,818 *

*
As the general partner to Safinia, LCSLS has shared voting and dispositive power over these Shares. As the
investment advisor
to Safinia, LCS has shared voting and dispositive power over these Shares.

(c)       Safinia
has not undertaken any transactions in the Shares since the filing of Amendment No. 2.

H. LCSLS

(a)  As
the General Partner of Safinia, LCSLS is deemed to beneficially own the 19,818 Shares beneficially
owned by Safinia.

Percentage: Less than 1.0%.

(b) 1. Sole power to vote or direct vote: 0
2. Shared power to vote or direct vote: 19,818 *
3. Sole power to dispose or direct the disposition: 0
4. Shared power to dispose or direct the disposition: 19,818 *
14

Follow Standard Biotools Inc. (NASDAQ:LAB)

Page 15 of 18 – SEC Filing

*
As the
general partner to Safinia, LCSLS has shared voting and dispositive power over these
Shares. As the investment advisor to Safinia, LCS has shared voting and dispositive power over these Shares.

(c)       LCSLS
has not undertaken any transactions in the Shares since the filing of Amendment No. 2.

I. John Levin

(a)  As
the Chief Executive Officer of LCS and the Managing Member of each of LCSL, LCSEP and LCSLS, Mr. Levin is deemed to beneficially
own 12,424,234 Shares beneficially owned by LCS. Mr. John Levin’s wife beneficially owns an additional 5,000 shares.

Percentage: Approximately 32.2%.

(b) 1. Sole power to vote or direct vote: 5,000
2. Shared power to vote or direct vote: 9,314,997
3. Sole power to dispose or direct the disposition: 5,000
4. Shared power to dispose or direct the disposition: 12,424,234

(c)       The
transactions in the Shares by Mr. Levin since the filing of Amendment No. 2 are set forth in Schedule A and are incorporated herein
by reference.

The filing of this
Schedule 13D shall not be construed as an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities
Exchange Act of 1934, as amended, the beneficial owners of any of the securities reported herein. Each of the Reporting Persons
specifically disclaims beneficial ownership of the securities reported herein that are not directly owned by such Reporting Person,
except to the extent of their pecuniary interest therein.

To the best of the
Reporting Persons’ knowledge, none of the persons listed on Appendix A beneficially owns any securities of the Issuer.

(d)       A
separately managed account, Transamerica, a registered investment company under the Investment
Company Act of 1940, as amended, for which LCS acts as sub-investment advisor, has the right to receive dividends from, and the
proceeds from the sale of, 1,275,129 Shares. Voting and dispositive power over such Shares is deemed to be shared between LCS and
Transamerica.

Various other separately
managed accounts for whom LCS acts as investment manager have the right to receive dividends from, and the proceeds from the sale
of 10,983,104 Shares. Dispositive power over such Shares is shared. Voting power over such Shares is deemed shared between such
managed accounts and LCS with respect to 9,314,997 Shares.

15

Follow Standard Biotools Inc. (NASDAQ:LAB)

Page 16 of 18 – SEC Filing

SIGNATURES

After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information
set forth in this statement is true, complete and correct. 

Dated: March 6, 2018

Levin Capital Strategies, L.P.
By:

/s/ John A. Levin

Name: John A. Levin
Title: Chief Executive Officer
Levin Capital Strategies GP, LLC
By: John A. Levin 2005 GRAT Separation Trust, as Managing Member
By:

/s/ Elisabeth Levin

Name: Elisabeth Levin
Title: Trustee
Bi-Directional Disequilibrium Master Fund, Ltd.
By: By: LCS, LLC, its General Partner
By:

/s/ John A. Levin

Name: John A. Levin
Title: Managing Member
LCS, LLC
By:

/s/ John A. Levin

Name: John A. Levin
Title: Managing Member
Levcap Alternative Fund, L.P
By: By: LCS Event Partners, LLC, its General Partner
By:

/s/ John A. Levin

Name: John A. Levin
Title: Managing Member
LCS Event Partners, LLC
By:

/s/ John A. Levin

Name: John A. Levin
Title: Managing Member
16

Follow Standard Biotools Inc. (NASDAQ:LAB)

Page 17 of 18 – SEC Filing

Safinia Partners, L.P.
By: LCS L/S, LLC, its General Partner
By:

/s/ John
A. Levin

Name: John A. Levin
Title: Managing Member
LCS L/S, LLC
By:

/s/ John
A. Levin

Name: John A. Levin
Title: Managing Member

/s/ John
A. Levin

John A. Levin
17

Follow Standard Biotools Inc. (NASDAQ:LAB)

Page 18 of 18 – SEC Filing

Schedule A

Transactions in the Shares Since the Filing
of Amendment No. 2

 

Date

Code

Quantity

Gross Price

Reporting Persons

3/2/2018 Buy 221,174 6.2392 Levin Capital Strategies, L.P.
3/2/2018 Buy 13,745 6.2497 Levin Capital Strategies, L.P.
3/2/2018 Buy 6,327 6.2392 Bi-Directional Disequilibrium Master Fund, Ltd.
3/2/2018 Buy 170 6.25 Levin Capital Strategies, L.P.
3/2/2018 Buy 415 6.25 Levin Capital Strategies, L.P.
3/2/2018 Buy 6,824 6.3735 Levin Capital Strategies, L.P.
3/1/2018 Buy 100 6.6525 Levin Capital Strategies, L.P.
3/1/2018 Buy 1,600 6.7269 Levin Capital Strategies, L.P.
2/28/2018 Buy 8,950 6.797 Levin Capital Strategies, L.P.
2/27/2018 Buy 5,000 6.8673 Levin Capital Strategies, L.P.
2/15/2018 Buy 5,000 7.8558 Levin Capital Strategies, L.P.
2/15/2018 Buy 5,000 7.8558 John Levin’s Wife
2/8/2018 Buy 12,338 5.7398 Levin Capital Strategies, L.P.
2/7/2018 Buy 3,100 5.6087 Levin Capital Strategies, L.P.
2/6/2018 Buy 50,510 5.7414 Levin Capital Strategies, L.P.
2/5/2018 Buy 33,887 5.9157 Levin Capital Strategies, L.P.
2/2/2018 Buy 17,100 6.0521 Levin Capital Strategies, L.P.
2/1/2018 Buy 7,866 6.1152 Levin Capital Strategies, L.P.
1/31/2018 Buy 136,850 6.177 Levin Capital Strategies, L.P.
1/31/2018 Buy 8,175 6.2694 Levin Capital Strategies, L.P.
1/23/2018 Buy 2,995 6.6861 Levin Capital Strategies, L.P.
1/22/2018 Buy 3,876 6.4759 Levin Capital Strategies, L.P.
1/16/2018 Buy 887 6.6829 Levin Capital Strategies, L.P.
1/10/2018 Buy 21 6.1362 Levin Capital Strategies, L.P.
1/10/2018 Buy 35,129 6.1363 Levin Capital Strategies, L.P.*
1/10/2018 Buy 50 6.1364 Levin Capital Strategies, L.P.
1/9/2018 Buy 17,927 6.445 Levin Capital Strategies, L.P.
1/9/2018 Buy 47,434 6.445 Levin Capital Strategies, L.P.*
1/9/2018 Buy 15 6.4453 Levin Capital Strategies, L.P.

* Trade made on behalf of separately managed account Transamerica
Large Cap Value Fund.

Follow Standard Biotools Inc. (NASDAQ:LAB)